Endocrine Abstracts

Background: Acromegaly is a slowly progressive rare disease caused by an increase in growth hormone secretion that causes a subsequent rise in insulin-like growth factor (IGF-1), both contributing to the excessive growth of the extremities, soft tissues and organs, in addition to other comorbidities directly interfering with patient’s quality of life. Acromegaly patients are concerned about their disease and their treatments, however, publications about patient’s opi...

Background: The goals of acromegaly treatment are to achieve long-term biochemical control, control tumor size and decrease the risk of developing systemic comorbidities. Moreover, from the patient’s perspective, symptoms and QoL are critical parameters of disease control and should be assessed routinely. To aid in the global clinical management of acromegaly, a holistic clinical decision support tool, the Acromegaly Disease Activity Tool (ACRODAT®) was developed.</p...